The DPY30-H3K4me3 Axis-Mediated PD-L1 Expression in Melanoma

References

• Larkin J, Chiarion-Sileni V, Gonzalez R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532. doi:10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rohmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247–257. doi:10.1016/j.ejca.2017.06.028
   PubMed Web of Science ®Google Scholar
• Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018;392(10151):971–984. doi:10.1016/s0140-6736(18)31559-9
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–856. doi:10.1158/1535-7163.MCT-14-0983
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27(3):409–416. doi:10.1093/annonc/mdv615
   PubMed Web of Science ®Google Scholar
• Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13(2):95–109. doi:10.1016/s1359-6101(01)00038-7
   PubMed Web of Science ®Google Scholar
• Benci JL, Xu B, Qiu Y, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167(6):1540–54 e12. doi:10.1016/j.cell.2016.11.022
   PubMed Web of Science ®Google Scholar
• Mimura K, Teh JL, Okayama H, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 2018;109(1):43–53. doi:10.1111/cas.13424
   PubMed Web of Science ®Google Scholar
• Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359–370. doi:10.1016/j.molcel.2019.09.030
   PubMed Web of Science ®Google Scholar
• Wu M, Huang Q, Xie Y, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24. doi:10.1186/s13045-022-01242-2
   PubMed Web of Science ®Google Scholar
• Casey SC, Tong L, Li Y, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352(6282):227–231. doi:10.1126/science.aac9935
   PubMed Web of Science ®Google Scholar
• Wu R, Wang C, Li Z, et al. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. J Immunother Cancer. 2020;8(2):e001037. doi:10.1136/jitc-2020-001037
   PubMed Web of Science ®Google Scholar
• Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84–88. doi:10.1038/nm1517
   PubMed Web of Science ®Google Scholar
• Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 2005;6(11):838–849. doi:10.1038/nrm1761
   PubMed Web of Science ®Google Scholar
• Soares LM, He PC, Chun Y, Suh H, Kim T, Buratowski S. Determinants of histone H3K4 methylation patterns. Mol Cell. 2017;68(4):773–85 e6. doi:10.1016/j.molcel.2017.10.013
   PubMed Web of Science ®Google Scholar
• Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem. 2012;81:65–95. doi:10.1146/annurev-biochem-051710-134100
   PubMed Web of Science ®Google Scholar
• Jiang H, Shukla A, Wang X, Chen WY, Bernstein BE, Roeder RG. Role for Dpy-30 in ES cell-fate specification by regulation of H3K4 methylation within bivalent domains. Cell. 2011;144(4):513–525. doi:10.1016/j.cell.2011.01.020
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang S, Li A, Zhang A, Zhang S. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells. Int J Mol Med. 2018;42(6):3065–3072. doi:10.3892/ijmm.2018.3869
   PubMed Web of Science ®Google Scholar
• Yang Z, Augustin J, Chang C, et al. The DPY30 subunit in SET1/MLL complexes regulates the proliferation and differentiation of hematopoietic progenitor cells. Blood. 2014;124(13):2025–2033. doi:10.1182/blood-2014-01-549220
   PubMed Web of Science ®Google Scholar
• Simboeck E, Gutierrez A, Cozzuto L, et al. DPY30 regulates pathways in cellular senescence through ID protein expression. EMBO J. 2013;32(16):2217–2230. doi:10.1038/emboj.2013.159
   PubMed Web of Science ®Google Scholar
• Sun L, Guo C, Cao J, et al. Over-expression of alpha-enolase as a prognostic biomarker in patients with pancreatic cancer. Int J Med Sci. 2017;14(7):655–661. doi:10.7150/ijms.18736
   PubMed Web of Science ®Google Scholar
• Hong ZF, Zhang WQ, Wang SJ, et al. Upregulation of DPY30 promotes cell proliferation and predicts a poor prognosis in cholangiocarcinoma. Biomed Pharmacother. 2020;123:109766. doi:10.1016/j.biopha.2019.109766
   PubMed Web of Science ®Google Scholar
• Li T, Zhang C, Zhao G, et al. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Lett. 2020;477:19–30. doi:10.1016/j.canlet.2020.02.036
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461. doi:10.1016/j.ccell.2015.03.001
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501. doi:10.1056/NEJMc1713444
   PubMed Web of Science ®Google Scholar
• Peng M, Mo Y, Wang Y, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128. doi:10.1186/s12943-019-1055-6
   PubMed Web of Science ®Google Scholar
• Liu B. DPY30 functions in glucose homeostasis via integrating activated histone epigenetic modifications. Biochem Biophys Res Commun. 2018;507(1–4):286–290. doi:10.1016/j.bbrc.2018.11.023
   PubMed Web of Science ®Google Scholar
• He FX, Zhang LL, Jin PF, Liu DD, Li AH. DPY30 regulates cervical squamous cell carcinoma by mediating epithelial-mesenchymal transition (EMT). Onco Targets Ther. 2019;12:7139–7147. doi:10.2147/OTT.S209315
   PubMed Web of Science ®Google Scholar
• Flausino CS, Daniel FI, Modolo F. DNA methylation in oral squamous cell carcinoma: from its role in carcinogenesis to potential inhibitor drugs. Crit Rev Oncol Hematol. 2021;164:103399. doi:10.1016/j.critrevonc.2021.103399
   PubMed Web of Science ®Google Scholar
• Zhang J, Yin J, Luo L, et al. Integrative analysis of DNA methylation and transcriptome identifies a predictive epigenetic signature associated with immune infiltration in gliomas. Front Cell Dev Biol. 2021;9:670854. doi:10.3389/fcell.2021.670854
   PubMed Web of Science ®Google Scholar
• Koch A, Joosten SC, Feng Z, et al. Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncol. 2018;15(7):459–466. doi:10.1038/s41571-018-0004-4
   PubMed Web of Science ®Google Scholar
• Villanueva A, Portela A, Sayols S, et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology. 2015;61(6):1945–1956. doi:10.1002/hep.27732
   PubMed Web of Science ®Google Scholar
• Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012;22(2):271–282. doi:10.1101/gr.117523.110
   PubMed Web of Science ®Google Scholar
• Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–1492. doi:10.1093/annonc/mdw168
   PubMed Web of Science ®Google Scholar
• Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002–1014. doi:10.1016/s0140-6736(21)01206-x
   PubMed Web of Science ®Google Scholar
• Pires da Silva I, Ahmed T, Reijers ILM, et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22(6):836–847. doi:10.1016/s1470-2045(21)00097-8
   PubMed Web of Science ®Google Scholar
• Shilatifard A. Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol. 2008;20(3):341–348. doi:10.1016/j.ceb.2008.03.019
   PubMed Web of Science ®Google Scholar
• Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell. 2007;25(1):15–30. doi:10.1016/j.molcel.2006.12.014
   PubMed Web of Science ®Google Scholar
• Vedadi M, Blazer L, Eram MS, Barsyte-Lovejoy D, Arrowsmith CH, Hajian T. Targeting human SET1/MLL family of proteins. Protein Sci. 2017;26(4):662–676. doi:10.1002/pro.3129
   PubMed Web of Science ®Google Scholar
• Lu K, Tao H, Si X, Chen Q. The histone H3 lysine 4 presenter WDR5 as an oncogenic protein and novel epigenetic target in cancer. Front Oncol. 2018;8:502. doi:10.3389/fonc.2018.00502
   PubMed Web of Science ®Google Scholar
• Jiang H. The complex activities of the SET1/MLL complex core subunits in development and disease. Biochim Biophys Acta Gene Regul Mech. 2020;1863(7):194560. doi:10.1016/j.bbagrm.2020.194560
   PubMed Web of Science ®Google Scholar
• Dou Y, Milne TA, Ruthenburg AJ, et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol. 2006;13(8):713–719. doi:10.1038/nsmb1128
   PubMed Web of Science ®Google Scholar
• Lu C, Paschall AV, Shi H, et al. The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion. J Natl Cancer Inst. 2017;109(6):djw283. doi:10.1093/jnci/djw283
   PubMedGoogle Scholar
• Xiong W, Deng H, Huang C, et al. MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity. Biochim Biophys Acta Mol Basis Dis. 2019;1865(2):454–463. doi:10.1016/j.bbadis.2018.10.027
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhou Q, Xie K, et al. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer. J Exp Clin Cancer Res. 2021;40(1):203. doi:10.1186/s13046-021-01989-5
   PubMed Web of Science ®Google Scholar
• Yang Z, Shah K, Busby T, et al. Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer. J Clin Invest. 2018;128(8):3605–3618. doi:10.1172/JCI97072
   PubMed Web of Science ®Google Scholar
• Dixit D, Prager BC, Gimple RC, et al. Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases. Sci Transl Med. 2022;14(626):eabf3917. doi:10.1126/scitranslmed.abf3917
   PubMed Web of Science ®Google Scholar